{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Progression-free survival rate at 12 months. PFS: determined as the time from administration of the initial dose of axitinib until objective tumor progression using Response Evaluation Criteria In Solid Tumors (RECIST), or death. Progressive Disease (PD) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. Stable Disease (SD): Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","groups":[{"description":"The investigational drug used in this study is axitinib, and is available as tablets.","id":"OG000","title":"Axitinib Administration"}],"paramType":"NUMBER","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Rate of Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}